The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A Pilot Dose-Escalation Safety Study of Tenecteplase in Acute Ischemic Stroke
Open accessAbstract
Background and Purpose— Recombinant tissue-type plasminogen activator (rtPA) is the only approved treatment in acute ischemic stroke. However, intracerebral hemorrhage (ICH) occurs in 6.4% of patients treated with rtPA and limits its use. Tenecteplase (TNK) is a modified form of rtPA, with longer half-life and greater fibrin specificity. Patients after myocardial infarction had fewer systemic hemorrhages when treated with TNK compared with rtPA. This open-label, dose-escalation safety study was conducted to develop initial experience with TNK in the treatment of ischemic stroke. Methods— Eligible patients were treated with an intravenous bolus infusion of TNK within 3 hours of stroke onset. The dose escalation was conducted in tiers of 25 patients, starting at 0.1 mg/kg, to a planned maximum of 0.6 mg/kg. The primary endpoint was symptomatic intracranial hemorrhage within 36 hours of treatment. All patients were followed-up for 3 months. Results— Eighty-eight (88) patients were treated in 4 dosing tiers. In the first 3 tiers (0.1, 0.2, 0.4 mg/kg) of 25 patients each, no symptomatic and 2 (8%), 8 (32%), and 7 (28%) asymptomatic ICHs occurred. Enrollment into the fourth tier at 0.5 mg/kg was closed after 2 of 13 patients (15%) had symptomatic and 3 (23%) had asymptomatic ICHs. Overall, modified Rankin scores at 3 months were similar to those of historical controls treated with rtPA and not significantly different between treatment groups. Conclusions— TNK doses of 0.1 to 0.4 mg/kg are safe in ischemic stroke. Future trials are needed to compare the effect of TNK on neurological outcome and safety as compared with rtPA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Cited by
Thrombolysis for acute ischaemic stroke
Wardlaw, J. M., Murray, V., Berge, E., & del Zoppo, G. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000213.pub3 · Cited by 1,370
Adams, H. P., del Zoppo, G., Alberts, M. J., Bhatt, D. L., Brass, L., Furlan, A., Grubb, R. L., Higashida, R. T., Jauch, E. C., Kidwell, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181486 · Cited by 904
Self-citationDurukan, A., & Tatlisumak, T. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.04.015 · Cited by 730
Wang, Y., Li, S., Pan, Y., Li, H., Parsons, M. W., Campbell, B. C. V., Schwamm, L. H., Fisher, M., Che, F., Dai, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02600-9 · Cited by 316
Haley, E. C., Thompson, J. L. P., Grotta, J. C., Lyden, P. D., Hemmen, T. G., Brown, D. L., Fanale, C., Libman, R., Kwiatkowski, T. G., Llinas, R. H., et al. (2010) · Stroke · doi:10.1161/strokeaha.109.572040 · Cited by 271
Self-citation
Metadata
- Authors
- Haley, E. C., Lyden, P. D., Johnston, K. C., Hemmen, T. M., & the TNK in Stroke Investigators
- Venue
- Stroke
- Published
- 2005-03
- Volume
- 36
- Issue
- 3
- Pages
- 607-612
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2105402180
- Cited by
- 222
- References
- 2
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Pilot Dose-Escalation Safety Study of Tenecteplase in Acute Ischemic Stroke. https://app.cochat.ai/papers/10.1161/01.str.0000154872.73240.e9
- The paper
- Haley, E. C., Lyden, P. D., Johnston, K. C., Hemmen, T. M., & the TNK in Stroke Investigators. (2005). A Pilot Dose-Escalation Safety Study of Tenecteplase in Acute Ischemic Stroke. Stroke. https://doi.org/10.1161/01.str.0000154872.73240.e9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.